<DOC>
	<DOCNO>NCT01009775</DOCNO>
	<brief_summary>The purpose study evaluate survival , response rate , safety tolerability YM155 give combination docetaxel subject Stage III ( unresectable ) Stage IV melanoma .</brief_summary>
	<brief_title>A Study YM155 Plus Docetaxel Subjects With Stage III ( Unresectable ) Stage IV Melanoma</brief_title>
	<detailed_description>All subject receive YM155 docetaxel give 21-day cycle . The docetaxel dose establish base finding lead-in portion study ( Part 1 ) . Once docetaxel dose establish , Part 2 enrollment begin . Part 1 : Part 1 lead-in stage confirm YM155 safely administer combination docetaxel specify dose . Part 2 : Subjects enrol Part 2 receive YM155 docetaxel dose establish Part 1 .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically cytologically confirm Stage III ( unresectable ) Stage IV melanoma No prior systemic treatment Cytotoxic chemotherapy advance melanoma ( Stage III Stage IV ) If subject female , must nonpregnant nonlactating Baseline Visit . All sexually active male female childbearing potential must agree use adequate method contraception throughout study period Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 1 Life expectancy &gt; 12 week At least one measurable target lesion accord Response Evaluation Criteria Solid Tumors ( { RECIST } version 1.1 ) Subjects previous history nonmelanoma malignancy must undergo curative therapy prior malignancy consider disease free least 5 year Major surgery within 21 day Baseline Visit Presence history brain metastasis Primary ocular , choroidal mucosal melanoma Known history positive test Hepatitis B surface Antigen ( HsbAg ) Hepatitis C antibody history positive test Human Immunodeficiency Virus ( HIV ) Hypersensitivity docetaxel polysorbate 80 Neuropathy great equal Grade 2 Baseline Visit The subject previously treat YM155 Inadequate marrow , hepatic , and/or renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Melanoma , Stage III</keyword>
	<keyword>Melanoma , Stage IV</keyword>
	<keyword>YM 155</keyword>
	<keyword>Metastatic Melanoma</keyword>
</DOC>